Articles tagged with Vaccine Development
A new study published in Clinical Infectious Diseases reveals that up to four out of ten children in Burkina Faso are genetically resistant to rotavirus strains found in existing vaccines. Children who cannot express the Lewis molecule, a sugar molecule needed as a receptor for the virus, do not become infected and therefore do not rec...
The University of Maryland School of Medicine has begun a clinical trial in health care workers in Mali to evaluate a promising experimental Ebola vaccine. The vaccine, developed by the Vaccine Research Center at NIAID, has shown highly protective immune responses in animal model challenge studies.
A new study suggests that vaccines developed for adolescents and adults could have a significant impact on tuberculosis (TB) worldwide. The researchers found that these vaccines could provide dramatic levels of control needed to eliminate TB by 2050. However, the current BCG vaccine given to infants is not enough to achieve this goal.
Researchers are developing a fingerprint-based recognition method to track vaccination schedules for infants and toddlers, increasing immunization coverage in developing countries. Fingerprints can accurately record immunizations, overcoming issues with lost or destroyed paper documents.
Neglected tropical diseases (NTDs) affect 14-15% of cases in Bolivia, Ecuador, Nicaragua, and Venezuela, despite the countries' small population. The US could work with these countries to implement disease control programs and develop lifesaving vaccines through joint efforts.
The Global Health Innovative Technology Fund (GHIT Fund) has awarded $15.3 million in grants to support the development of promising vaccines and drugs against three insect-borne diseases: malaria, dengue, and Chagas disease. These investments aim to tackle diseases that disproportionately affect the world's poorest populations.
Experts warn that dengue vaccines could lead to short-term spikes in disease incidence, but long-term vaccination will reduce overall infections. The issue arises from the natural fluctuations in mosquito populations and the imperfect vaccine protection.
Infant rhesus monkeys receiving different diets early in life develop distinct immune systems that persist months after weaning. Breast-fed macaques had more memory T cells and T helper 17 cells, which are known to fight Salmonella and other pathogens.
Researchers led by the University of Bonn have found that the MERS virus has a low transmission rate from person to person, but is still a deadly disease. The study, published in the New England Journal of Medicine, also suggests that dromedaries may be an additional source of infection.
A candidate Ebola vaccine is being tested on healthy volunteers in the UK, The Gambia, and Mali as part of an international collaboration. The phase 1 trials aim to ensure the vaccine's safety and immunogenicity before deployment to high-risk populations.
A new strategy for generating broadly cross-reactive antibodies has been developed against the H5N1 flu virus. Researchers found that human volunteers immunized with the H5N1 virus generated antibodies against the stem region of the viral hemagglutinin protein, which could provide protection against a variety of flu strains.
Karl Klose, a UTSA microbiologist, has received a $1 million contract from the US Department of Defense to develop a vaccine against tularemia. The bacteria can be deadly and has been developed as a bioweapon by several countries.
Scientists have discovered novel properties of special HIV antibodies that can neutralize multiple strains of HIV. The study found that these 'broadly neutralizing antibodies' are more prevalent in HIV-infected individuals than previously thought, suggesting a possible vaccine strategy to elicit them.
Researchers at Virginia Commonwealth University School of Medicine have identified three surface proteins on the Anaplasma phagocytophilum bacterium that cause tick-transmitted disease. Targeting these proteins could lead to effective prevention and treatment, enabling the development of a vaccine.
Research reveals that chronic infections impair the development of immune cell memory, reducing vaccine effectiveness. The study found that bystander chronic infections impede the transition of effector T cells to memory T cells.
Dan Granoff, a CHORI scientist, has been recognized with the prestigious Maurice Hilleman/Merck Award for his work on developing vaccines against serogroup B meningococcus and an affordable serogroup A meningococcal conjugate vaccine for Africa.
Patients with immunosuppressive conditions are at high risk of shingles but lack access to vaccination due to safety concerns. Alternative strategies must be developed to reduce shingles risk among these patient groups.
Researchers at the University of Texas Medical Branch are working on a universal flu vaccine that could eliminate the need for annual flu shots. With a $4.4 million grant, they plan to test a vaccine containing antigens from A and B strains of influenza, aiming for approval within five years.
A new experimental vaccine developed by Novavax has been shown to induce a neutralizing antibody response in mice, blocking infection with the MERS-CoV virus. The vaccine uses recombinant nanoparticle technology and is based on the major surface spike protein of SARS-CoV and MERS-CoV.
Roy Curtiss, a pioneer in recombinant DNA era gene cloning and novel bacterial pathogenesis research, has made significant contributions to developing attenuated Salmonella-based vaccines. His work has improved human health through combating infectious diseases, particularly pneumonia, tuberculosis, and influenza.
Neglected tropical diseases (NTDs) threaten Indonesia's economic growth and development, particularly for women and children. The country has an opportunity to scale up national programs and integrate NTDs with other development efforts.
Researchers have discovered a novel immunological mechanism that regulates B lymphocytes to fight encapsulated bacteria, clearing the path for more efficient vaccines. This discovery improves our understanding of the immune system's protection against infections.
Hepatitis C affects 160 million worldwide, with 3.2 million Americans infected. The Rutgers study identifies the virus's outer protein structure, which enables evasion of the immune system.
Scientists at the University of Edinburgh have developed a novel way to produce malaria parasite proteins that could lead to easy and cheap vaccine manufacturing. The new approach uses a single-celled aquatic creature similar to the malaria parasite, allowing for rapid multiplication in the lab.
A team of scientists has discovered the structure of the NS1 protein, which helps dengue and West Nile viruses replicate and evade the immune system. The researchers believe this breakthrough could lead to the development of a vaccine that protects people without increasing their risk.
A safe and effective HIV vaccine is necessary to control and potentially end the HIV/AIDS pandemic. Recent scientific advances offer promising areas for further exploration, including the discovery of broadly neutralizing antibodies and improved understanding of T-cell responses.
A safe and effective HIV vaccine is necessary to control and end the AIDS pandemic, according to a new commentary by NIAID Director Anthony S. Fauci. Recent advances in understanding broadly neutralizing antibodies and T-cell responses offer promising areas for further exploration.
Researchers developed a novel method to study enterovirus structures and functions, allowing for tracking of viruses in cells and tissues. The method involves attaching gold nanoparticles to viruses, enabling studies on structural changes and mechanisms of virus uncoating.
A new intranasal vaccine against pertussis has been successfully tested in humans, inducing an immune response that lasted for at least 6 months. The vaccine was found to be safe and effective, with no adverse events reported even at the high dose.
A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, by wrapping it in a polymer chain. This discovery could lead to the development of stable vaccines and affordable artificial blood substitutes.
A study published in Neurology suggests that a vaccine used to prevent tuberculosis may help prevent multiple sclerosis in people showing early signs of the disease. After six months, vaccinated individuals had fewer brain lesions than those who received a placebo, with 58% not developing MS compared to 30%.
A new rabies vaccine aims to develop a single dose contraceptive vaccine, reducing child deaths and controlling dog rabies. The vaccine targets dendritic cells to induce strong immune responses against rabies and foreign antigens.
The updated 2013 Malaria Vaccine Technology Roadmap sets a new target for vaccines to reduce malaria cases by 75 percent and be licensed by 2030. The roadmap also aims for malaria elimination through the development of safe and effective vaccines that prevent disease, death, and transmission.
Researchers identified a genetic signature for respiratory syncytial virus (RSV), which causes severe pneumonia and bronchiolitis in infants. The discovery will help develop a vaccine and improve disease severity prediction using RNA profiles.
Professor Alan Cowman has been recognized for his substantial contributions to understanding malaria development and drug resistance. His work has led to the development of two potential malaria vaccines, one in clinical trials and the other in preclinical development.
A three-year project aims to create an oral vaccine against C. difficile, which kills thousands annually. The novel approach uses harmless bacterial spores to boost immunity and targets the protein needed for the infection to take hold.
Researchers say Chagas disease remains a leading cause of heart disease in impoverished North American communities, with inadequate healthcare and limited treatment options available. The editorial calls for increased medical awareness, scientific cooperation, and public-private partnerships to develop new tools and treatments.
Scientists at Arizona State University have developed a microchip-based technology called immunosignature diagnosis that can rapidly measure an individual's vaccine response. This innovation has the potential to significantly reduce the costs and timeframes of vaccine testing, allowing for more effective vaccines to be identified.
A clinical study published in The Lancet Infectious Diseases shows that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. This breakthrough finding has significant implications for vaccination strategies and cost-effectiveness in developing countries.
Professor Alan Cowman's work has led to a better understanding of malaria biology, informing new treatments and vaccines. The development of potential malaria vaccines is a significant step towards eradicating the disease.
A new research project will develop the next generation of effective mucosal vaccines using immunomodulation and cell-targeted nanoparticles. This innovation aims to improve vaccine administration in resource-poor settings, reducing blood-borne contamination and pandemic spread risks.
Researchers have developed a new tuberculosis vaccine that acts as a booster to the existing Bacille Calmette Guerin (BCG) vaccine, which is ineffective in many cases. The vaccine was tested in a phase one clinical study and showed a robust immune response in most trial participants.
Firdausi Qadri, a renowned Bangladeshi immunologist, has been awarded the prestigious C.N.R. Rao Prize for her groundbreaking research on enteric diseases and innovative mass immunization strategies. Her work aims to develop new approaches to combat common infectious diseases in developing countries.
A new consortium led by the Sabin Vaccine Institute is conducting clinical trials of a human hookworm vaccine in Gabon. The vaccine has the potential to dramatically improve health, economic, and social landscapes in countries with high burdens of hookworm disease.
Duke Medicine has been named a Vaccine and Treatment Evaluation Unit (VTEU) to evaluate vaccines, treatments, and diagnostics. The VTEU will focus on vaccine development for diseases other than HIV, with potential annual funding of up to $135 million.
The National Institutes of Health has awarded a nearly $1 billion contract to Saint Louis University's Center for Vaccine Development, recognizing the institution's leadership role in vaccine research. The seven-year contract will support clinical trials and lab studies for new vaccines, with a focus on emerging threats.
The National Institute of Allergy and Infectious Diseases has renewed a 10-year contract with the University of Maryland School of Medicine's Center for Vaccine Development, providing up to $135 million in annual funding. The center will conduct basic research, clinical studies, and vaccine development to combat existing and emerging i...
Researchers at Scripps Research Institute discovered that an antibody binding to HIV likely targets the body's own proteins, complicating its development as a vaccine. The finding raises concerns about potential autoimmune diseases and self-reactivity in 4E10 antibodies.
A novel vaccine approach against human cytomegalovirus (CMV) has been shown to be safe and more effective than previous vaccines in an animal model. The vaccine targets CMV's ability to hijack the immune system, inducing broader immunological protection.
Researchers developed a microneedle patch that delivered an effective and long-lasting influenza vaccine, providing 100% protection in mice over one year. The vaccine used virus-like particles coated on needles, reducing refrigeration needs and potential side effects.
Researchers developed a strain of rice that produces a rotavirus-specific antibody, protecting both normal and immune-deficient mice. The engineered rice maintains its efficacy even after long-term storage and heat exposure.
Researchers found that higher dosages of the PfSPZ Vaccine generated more antibodies and T cells, providing protection against malaria infection. The study's results suggest a potential breakthrough in developing a safe and effective malaria vaccine.
A new modular vaccine design called MAPS technology may generate vaccines conferring strong immunity at reduced cost and risk. The method allows for rapid construction of new vaccines that activate multiple arms of the immune system simultaneously against one or more pathogens, reducing the risk of adverse effects.
IDRI's VL vaccine candidate has shown safety and immunogenicity in healthy volunteers, and Zydus' expertise will be crucial in getting the vaccine to those who need it most. The partnership aims to make the vaccine affordable and accessible to all people in need, particularly in endemic countries.
Researchers have developed a vaccine that provides at least 60 percent protection against rotavirus in newborns, significantly reducing severe dehydration and hospitalizations. The study, published in the Journal of Infectious Diseases, suggests that early administration of the vaccine could save thousands of lives annually.
Research reveals higher diversity in gut microbiota enables more robust immune responses to vaccines. Scientists found that diverse gut bacteria may help humans resist enteric pathogens like Salmonella and Shigella.
Scientists at Emory Vaccine Center found that IL-21 is necessary for long-lasting antibody responses in mice against viral infections. The molecule stimulates germinal centers and supports T helper cells, leading to the generation of virus-specific long-lived plasma cells.
The India-developed rotavirus vaccine ROTAVAC has demonstrated excellent safety and efficacy in a Phase III clinical trial, reducing severe rotavirus diarrhoea by over half. The vaccine's impact extends beyond rotavirus infections, also showing protection against severe diarrhoea of any cause.
A new international study has pinpointed the main causes of childhood diarrheal diseases, identifying rotavirus as the leading cause among infants. The Global Enteric Multicenter Study found that targeting just four pathogens could prevent most cases and save hundreds of thousands of lives through vaccines and treatments.
The Bill & Melinda Gates Foundation has awarded a $2.9 million grant to Aeras, Oxford University, and Okairos to develop novel vaccines against tuberculosis, HIV, and malaria. The collaboration aims to create scalable methods for large-scale production of multiple chimpanzee adenovirus vector constructs.